As of 2025-05-16, the Fair Value of Oryzon Genomics SA (ORY.MC) is -0.23 EUR. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 2.64 EUR, the upside of Oryzon Genomics SA is -108.84%.
With the market price of 2.64 EUR and our fair value calculation, Oryzon Genomics SA (ORY.MC) is not a good investment. Investing in ORY.MC stocks now will result in a potential loss of 108.84%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | -3.40 | -4.69 | -4.23 | -3.35 | -3.67 | -3.87 |
| YoY growth | 7.61% | -37.94% | 9.78% | 20.76% | -9.32% | -1.82% |
| Market Cap (mil) | 207.37 |
| P/E | |
| Forward P/E |
| EPS | -0.05 |
| Avg earnings growth rate | -1.82% |
| TTM earnings | -3.67 |